The U.S. Food and Drug Administration has approved the marketing of a new tool to that can test a person’s blood to diagnose ...

The U.S. Food and Drug Administration has cleared Fujirebio Diagnostics' blood test to diagnose Alzheimer's disease, the ...

Nuravax and others are working on the next wave of Alzheimer’s treatments to catch the disease before symptoms arise.

Dublin, May 13, 2025 (GLOBE NEWSWIRE) -- The "Leqembi Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering.

Over the past decade, Ralph got involved with the Maine Running Club and began signing up for more road races. When he ...

Eisai and Biogen's Alzheimer's therapy Leqembi will be priced at $26,500 per year – a little less than misfired predecessor Aduhelm – after getting conditional authorisation for the drug from ...

Leqembi (lecanemab-irmb) is a prescription drug that’s used to treat Alzheimer’s disease. It comes as a liquid solution that healthcare professionals administer as an intravenous (IV ...

The European Commission has approved Eisai and Biogen's Leqembi for a subset of patients with early-stage Alzheimer's disease, setting it up to become the first amyloid-targeting drug to reach the ...

Alzheimer's disease prevalence is a primary driver of the Leqembi market. This degenerative brain disorder gradually impacts memory and cognition, influenced by genetic, lifestyle, and environmental ...

BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) today welcomes investors, analysts and financial media to the company's Capital Markets Day.

Seeking to grow prescriptions in the U.S., the Japanese drugmaker is now targeting TV advertising toward recently diagnosed Alzheimer’s disease patients. The launch of Leqembi got off to a slow ...

The test will initially be available at about 50 American research institutes and hospitals that specialise in Alzheimer’s ...